Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Melphalan drug delivery system - Delcath Systems

Drug Profile

Melphalan drug delivery system - Delcath Systems

Alternative Names: CHEMOSAT; CS-PHP-Melphalan; Generation Two CHEMOSAT Delivery System for Melphalan; Melblez Kit; Melphalan/HDS; Melphalan/Hepatic Delivery System

Latest Information Update: 13 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University School of Medicine
  • Developer Delcath Systems
  • Class Antineoplastics; Aromatic amino acids; Myeloablative agonists; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA damage stimulants; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Neuroendocrine tumours; Cholangiocarcinoma; Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Liver metastases
  • Phase II/III Cholangiocarcinoma
  • Phase II Liver cancer

Most Recent Events

  • 13 Feb 2019 Melphalan drug delivery system is available for licensing in Latin America, Brazil, as of 11 Feb 2019
  • 11 Feb 2019 Registered for Liver metastases (Inoperable/Unresectable) in Brazil (Intrahepatic)
  • 26 Dec 2018 Melphalan drug delivery system licensed to medac in European Union, Norway, Liechtenstein, Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top